| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2000;69:369-375
© 2000 The Society of Thoracic Surgeons
a Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
b Department of Medical Informatics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Address reprint requests to Dr Putnam, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 109, Houston, TX 77030
e-mail: putnam{at}mdanderson.org
Presented at the Forty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 12–14, 1998.
Background. Previous studies have shown that a chronic indwelling pleural catheter (PC) safely and effectively relieved dyspnea, maintained quality of life, and reduced hospitalization in patients with malignant pleural effusions. Outpatient management of malignant pleural effusion with a PC may reduce length of stay and early (7-day) charges compared with inpatient management with chest tube and sclerosis.
Methods. A retrospective review of consecutive PC patients (n = 100; 60 outpatient, 40 inpatient) were treated from July 1, 1994 to September 2, 1998 and compared with 68 consecutive inpatients treated with chest tube and sclerosis between January 1, 1994 and December 31, 1997. Hospital charges were obtained from date of insertion (day 0) through day 7.
Results. Demographics were similar in both groups. Pretreatment cytology was positive in 126 of 168 patients (75%), negative in 21 (12.5%), and unknown in 21 (12.5%). Primary histology included lung (n = 61, 36%), breast (n = 39, 23%), lymphoma (n = 12, 7%), or other (n = 56, 34%). Median survival was 3.4 months and did not differ significantly between treatment groups. Overall median length of stay was 7.0 days for inpatient chest tube and inpatient PC versus 0.0 days for outpatient Pleurx. No mortality occurred related to the PC. Eighty-one percent (81/100) of PC patients had no complications. One or more complications occurred in 19 patients (19%). Patients treated with outpatient PC (n = 60) had early (7-day) mean charges of $3,391 ± $1,753 compared with inpatient PC (n = 40, $11,188 ± $7,964) or inpatient chest tube (n = 68, $7,830 ± $4,497, SD) (p < 0.001).
Conclusions. Outpatient PC may be used effectively and safely to treat malignant pleural effusions. Hospitalization is not required in selected patients. Early (7-day) charges for malignant pleural effusion are reduced in outpatient PC patients compared with inpatient PC patients or chest tube plus sclerosis patients.
Related Article
Ann. Thorac. Surg. 2000 69: 375.
This article has been cited by other articles:
|
|
 |
|
  C. A. Efthymiou, T. Masudi, J. A. Charles Thorpe, and K. Papagiannopoulos Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunnelled catheters Interactive CardioVascular and Thoracic Surgery, December 1, 2009; 9(6): 961 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Buss Palliating Dyspnea for Patients with Cancer ASCO Educational Book, January 1, 2009; 2009(1): 549 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E Davies, Y C G. Lee, and R. J O Davies Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax, July 1, 2008; 63(7): 572 - 574. [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Warren, R. Kalimi, L. M. Khodadadian, and A. W. Kim Management of Malignant Pleural Effusions Using the Pleurx Catheter Ann. Thorac. Surg., March 1, 2008; 85(3): 1049 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Heffner and J. S. Klein Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions Mayo Clin. Proc., February 1, 2008; 83(2): 235 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Warren, A. W. Kim, and M. J. Liptay Identification of clinical factors predicting Pleurx (R) catheter removal in patients treated for malignant pleural effusion Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Daniel, I. Kriegel, S. Di Maria, G. Patrubani, R. Levesque, A. Livartowski, and M. Esteve Use of a Pleural Implantable Access System for the Management of Malignant Pleural Effusion: The Institut Curie Experience Ann. Thorac. Surg., October 1, 2007; 84(4): 1367 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tremblay, C. Mason, and G. Michaud Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis Eur. Respir. J., October 1, 2007; 30(4): 759 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Haas, D. H. Sterman, and A. I. Musani Malignant Pleural Effusions: Management Options With Consideration of Coding, Billing, and a Decision Approach Chest, September 1, 2007; 132(3): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kvale, P. A. Selecky, and U. B. S. Prakash Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 368S - 403S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Janes, N. M. Rahman, R. J. O. Davies, and Y. C. G. Lee Catheter-Tract Metastases Associated With Chronic Indwelling Pleural Catheters Chest, April 1, 2007; 131(4): 1232 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tan, A. Sedrakyan, J. Browne, S. Swift, and T. Treasure The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur. J. Cardiothorac. Surg., May 1, 2006; 29(5): 829 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tremblay and G. Michaud Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest, February 1, 2006; 129(2): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Medford and N Maskell Pleural effusion Postgrad. Med. J., November 1, 2005; 81(961): 702 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ren, D. S. Terman, G. Bohach, A. Silvers, C. Hansen, H. Colt, and S. A. Sahn Intrapleural Staphylococcal Superantigen Induces Resolution of Malignant Pleural Effusions and a Survival Benefit in Non-Small Cell Lung Cancer Chest, November 1, 2004; 126(5): 1529 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Migliore Efficacy and safety of single-trocar technique for minimally invasive surgery of the chest in the treatment of noncomplex pleural disease J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1618 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bernard, R. B. de Dompsure, O. Hagry, and J. P. Favre Early and late mortality after pleurodesis for malignant pleural effusion Ann. Thorac. Surg., July 1, 2002; 74(1): 213 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shoji, F. Tanaka, K. Yanagihara, K. Inui, and H. Wada Phase II Study of Repeated Intrapleural Chemotherapy Using Implantable Access System for Management of Malignant Pleural Effusion Chest, March 1, 2002; 121(3): 821 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.E. Martin-Ucar, J.G. Edwards, A. Rengajaran, S. Muller, and D.A. Waller Palliative surgical debulking in malignant mesothelioma : Predictors of survival and symptom control Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1117 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Pien, M. J. Gant, C. L. Washam, and D. H. Sterman Use of an Implantable Pleural Catheter for Trapped Lung Syndrome in Patients With Malignant Pleural Effusion Chest, June 1, 2001; 119(6): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
